Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Monoclonal Antibodies
Studies from ImClone Systems, Inc. in the area of monoclonal antibodies described
April 11th, 2007
New research, "Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys," is the subject of a report. According to recent research from the United States, "We generated three fully human monoclonal antibody antagonists against fibroblast growth factor receptor-1 (FGFR1) that potently block FGF signaling. We found that antibodies targeting the c-splice form of the receptor (FGFR1c) were anorexigenic when administered intraperitoneally three times weekly to mice, resulting in rapid, dose-dependent weight loss that plateaued (for doses >4 mg/kg) at 35-40% in 2 wk." "Animals appeared healthy...
Source: Immunotherapy Weekly (2007-04-11)
|
